#USA #Raleigh #Accord BioPharma #Bio-Thera #BAT2506

Accord BioPharma Expands Pipeline with BAT2506

Accord BioPharma, the specialty division of Intas Pharmaceuticals, has forged a significant partnership with Bio-Thera Solutions to develop its latest biosimilar product, BAT2506. This agreement marks Accord's commitment to increasing patient access to critical therapies, especially in the field of immunology.

Understanding BAT2506

BAT2506 is a biosimilar candidate targeting Simponi® (golimumab), a human monoclonal antibody effective at blocking tumor necrosis factor alpha (TNF-alpha) – a key player in various inflammatory conditions. The original product, Simponi®, is often prescribed for moderate to severe rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis. The high sales figures of Simponi®, reaching approximately $3.2 billion globally in 2023, illustrate the demand for effective treatments in this therapeutic space.

The Deal

Under this exclusive licensing agreement, Accord BioPharma will gain the rights to commercialize BAT2506 in the U.S. market, while Bio-Thera is responsible for its development, manufacturing, and supply. This delineation of roles allows Accord to leverage Bio-Thera’s expertise in product development while focusing on marketing and distribution strategies tailored to U.S. healthcare needs.

Chrys Kokino, the U.S. President of Accord, emphasized the importance of this growth strategy, stating, "Our U.S. portfolio of biosimilars continues to rapidly expand... We're strategically collaborating with select partners around the world to bring more biosimilars to the U.S. market as swiftly as possible." This sentiment is further echoed by Binish Chudgar, Executive Chairman of Intas Pharmaceuticals, highlighting the transformative potential of biosimilars within the healthcare landscape.

Market and Future Potential

The U.S. market for biologics is forecasted to grow at an impressive rate. Biosimilars, especially in immunology, present unique opportunities by offering cost-effective treatment options that enhance patient access to therapies that once seemed costly or out of reach. This partnership reinforces Accord BioPharma's commitment to improving the patient experience and ensuring that high-quality biologics are accessible to those in need.

Dr. Shengfeng Li, CEO of Bio-Thera, expressed his enthusiasm for the collaboration, stating, "Accord is a leading biosimilar company in the United States, and we are pleased to establish this commercial partnership for BAT2506." Together, they aim to broaden the range of immunology biosimilars available to American patients in the coming years.

About the Companies

Accord BioPharma focuses on creating affordable therapies primarily in oncology, immunology, and critical care. The company is dedicated to enhancing the patient experience by advancing a diverse pipeline of biosimilars that can help reduce healthcare costs for numerous patient populations that often struggle with the price of specialty medications.

Bio-Thera Solutions, based in Guangzhou, China, is well-established in researching and developing innovative therapeutics for various severe medical needs. This includes their efforts in biosimilars designed to tackle existing branded biologics, illustrating their commitment to improving healthcare outcomes globally.

As the biosimilar landscape rapidly evolves, the partnership between Accord BioPharma and Bio-Thera signifies a progressive step toward meeting the escalating demand for effective chronic disease treatments, particularly as the healthcare industry continues to seek solutions that blend efficacy with affordability for patients.